AMICUS THERAPEUTICS INC's ticker is FOLD and the CUSIP is 03152W109. A total of 249 filers reported holding AMICUS THERAPEUTICS INC in Q3 2020. The put-call ratio across all filers is 0.28 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2022 | $279,000 | -39.9% | 29,448 | -26.8% | 0.00% | – |
| Q4 2021 | $464,000 | +14.6% | 40,213 | -5.2% | 0.00% | – |
| Q3 2021 | $405,000 | -10.0% | 42,413 | -9.2% | 0.00% | – |
| Q2 2021 | $450,000 | -3.6% | 46,701 | -1.1% | 0.00% | – |
| Q1 2021 | $467,000 | -81.8% | 47,228 | -57.5% | 0.00% | -100.0% |
| Q4 2020 | $2,568,000 | -72.7% | 111,222 | -83.3% | 0.00% | -75.0% |
| Q3 2020 | $9,393,000 | -10.2% | 665,326 | -4.0% | 0.00% | -20.0% |
| Q2 2020 | $10,456,000 | +48.4% | 692,996 | -9.0% | 0.01% | +25.0% |
| Q1 2020 | $7,044,000 | +0.6% | 761,803 | +6.0% | 0.00% | +33.3% |
| Q4 2019 | $7,001,000 | +98.6% | 718,896 | +63.6% | 0.00% | +200.0% |
| Q3 2019 | $3,525,000 | +109.4% | 439,455 | +225.8% | 0.00% | 0.0% |
| Q2 2019 | $1,683,000 | -71.3% | 134,882 | -68.7% | 0.00% | -50.0% |
| Q1 2019 | $5,868,000 | -44.2% | 431,517 | -60.7% | 0.00% | -60.0% |
| Q4 2018 | $10,518,000 | +276.0% | 1,098,083 | +374.8% | 0.01% | +400.0% |
| Q3 2018 | $2,797,000 | -44.1% | 231,290 | -33.5% | 0.00% | -50.0% |
| Q4 2017 | $5,001,000 | -5.5% | 347,563 | -1.0% | 0.00% | 0.0% |
| Q3 2017 | $5,294,000 | +47.3% | 351,089 | -1.7% | 0.00% | 0.0% |
| Q2 2017 | $3,595,000 | +40.0% | 356,983 | -0.9% | 0.00% | +100.0% |
| Q1 2017 | $2,568,000 | +79.7% | 360,148 | +25.3% | 0.00% | 0.0% |
| Q4 2016 | $1,429,000 | -57.1% | 287,474 | -36.1% | 0.00% | -50.0% |
| Q3 2016 | $3,331,000 | +40.0% | 450,076 | +3.3% | 0.00% | +100.0% |
| Q2 2016 | $2,379,000 | +2165.7% | 435,736 | +3392.6% | 0.00% | – |
| Q1 2016 | $105,000 | +56.7% | 12,476 | +54.2% | 0.00% | – |
| Q4 2014 | $67,000 | +39.6% | 8,090 | 0.0% | 0.00% | – |
| Q3 2014 | $48,000 | +77.8% | 8,090 | 0.0% | 0.00% | – |
| Q2 2014 | $27,000 | -28.9% | 8,090 | -56.2% | 0.00% | – |
| Q1 2014 | $38,000 | -59.1% | 18,490 | -53.4% | 0.00% | – |
| Q4 2013 | $93,000 | -19.8% | 39,690 | -20.9% | 0.00% | – |
| Q3 2013 | $116,000 | +427.3% | 50,190 | +439.6% | 0.00% | – |
| Q2 2013 | $22,000 | – | 9,301 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Palo Alto Investors LP | 10,524,022 | $127,972,108 | 12.11% |
| Perceptive Advisors | 27,692,917 | $336,745,870 | 11.23% |
| Redmile Group, LLC | 16,944,621 | $206,046,591 | 9.80% |
| Finepoint Capital LP | 1,489,025 | $18,106,544 | 9.02% |
| CM Management, LLC | 450,000 | $5,472,000 | 5.81% |
| Avoro Capital Advisors LLC | 27,400,000 | $333,184,000 | 5.20% |
| MPM BioImpact LLC | 716,139 | $8,708,250 | 2.32% |
| Artal Group S.A. | 4,062,567 | $49,401 | 2.12% |
| SECTORAL ASSET MANAGEMENT INC | 803,464 | $9,770,122 | 1.90% |
| GREAT POINT PARTNERS LLC | 857,000 | $10,421,120 | 1.90% |